Cytokinetics (CYTK) EVP Fady Ibraham Malik Sells $224K of Stock

Cytokinetics, Incorporated EVP of Research & Development Fady Ibraham Malik sold 3,500 shares of the company on October 20, 2026. According to a Form 4 filing with the U.S. Securities and Exchange Commission, the transaction was executed at a price of $64.01 per share, for a total value of $224,035.

CYTK Cytokinetics, Incorporated

$63.95 ▲ +3.60% year to date

1M 3M YTD

Daily close · Oct 20, 2026

Inside Fady Ibraham Malik's CYTK Trade

The planned sale lowered Malik's holdings by 2.22%, leaving him with 153,902 shares of Cytokinetics following the transaction. The trade took place on the same day the biotechnology company's shares closed at $63.95.

Other Institutional Activity in Cytokinetics

Avoro Capital Advisors LLC grew its holdings by 1,666,666 shares, ending with 4,999,999 shares worth about $319,749,939. Avoro Capital Advisors also held 3,333,333 shares valued at about $283,966,646.

Cytokinetics, Incorporated Stock Up 2.9%

Cytokinetics recently traded around $63.72 on October 20, 2026, down about 0.4% from its event-day close of $63.95. The stock sits below its 50-day moving average of $69.98 and its 200-day moving average of $70.13. Shares have traded between a 52-week low of $54.30 and a high of $88.31, putting the recent price about 17.3% above the low and 27.8% below the peak. This transaction arrives just weeks before the company reports its next financial results.

Recent Earnings

For the trailing twelve months, Cytokinetics posted $67.67 million in revenue with an EPS of -$7.22. The company is scheduled to release its next financial results on November 4, 2026.

Insider Buying and Selling at Cytokinetics, Incorporated

Insider transactions earlier included CEO Robert I. Blum selling 7,500 shares for $490,950 on September 28, 2026. Fady Ibraham Malik previously sold 3,500 shares for $214,830 on October 6, 2026. Blum also executed a planned sale of 7,500 shares for $471,600 on October 12, 2026, alongside an identical non-planned sale of 7,500 shares for $471,600 on the same date.

Analysts Set New Price Targets

Barclays maintained an Overweight rating on August 13, 2026, lifting its target from $95.00 to $110.00. HC Wainwright & Co. reiterated a Buy rating with a $140.00 target on August 31, 2026, and again on October 19, 2026. RBC Capital maintained an Outperform rating while adjusting its target from $112.00 to $113.00 on October 8, 2026. William Blair initiated coverage with an Outperform rating on October 16, 2026. Overall, the stock holds a consensus strong buy rating from 20 analysts with a mean price target of $109.20.

About Cytokinetics

Headquartered in South San Francisco, California, Cytokinetics develops muscle activators and inhibitors to treat debilitating conditions. Its portfolio features MYQORZO, a cardiac myosin inhibitor designed for symptomatic obstructive hypertrophic cardiomyopathy. Executive transactions at the biopharmaceutical firm draw attention as the company moves toward upcoming clinical updates and earnings disclosures.

Bottom Line

Investors will watch the upcoming earnings report on November 4, 2026, for further financial updates. Form 4 filings will continue to track executive ownership changes as the stock navigates its current trading range.